• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23529 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     NIHR Health Technology Assessment programme KardiaMobile 6L for measuring QT interval in people having antipsychotic medication to inform early value assessment: a systematic review
2024     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation
2024     NIHR Health Technology Assessment programme Patient-reported outcome measures for monitoring primary care patients with depression: the PROMDEP cluster RCT and economic evaluation
2024     NIHR Health Technology Assessment programme Prehospital early warning scores for adults with suspected sepsis: the PHEWS observational cohort and decision-analytic modelling study
2024     NIHR Health Services and Delivery Research programme Reducing health inequalities through general practice: a realist review and action framework
2024     NIHR Health Services and Delivery Research programme Safer and more efficient vital signs monitoring protocols to identify the deteriorating patients in the general hospital ward: an observational study
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Functional dysphagia therapy up to 5 weeks after oncological therapy: Evidence report for the S3 guideline „Oropharyngeal dysphagia“ due to head and neck tumours – diagnosis and treatment]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Functional dysphagia therapy at least 6 weeks after oncological therapy: Evidence report for the S3 guideline „Oropharyngeal dysphagia“ due to head and neck tumours – diagnosis and treatment]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Core decompression: Evidence report for the S3 guideline on atraumatic femoral head necrosis in adults]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hyperbaric oxygen therapy: Evidence report for the S3 guideline on atraumatic femoral head necrosis in adults]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bisphosphonates: Evidence report for the S3 guideline on atraumatic femoral head necrosis in adults]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Total hip arthroplasty (THA) using a short stem: Evidence report for the S3 guideline on atraumatic femoral head necrosis in adults]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hyperbaric oxygen therapy vs. core decompression: Evidence report for the S3 guideline on atraumatic femoral head necrosis in adults]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for back surgery]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome in surgery for gastric cancer and cancer of the gastro-oesophageal junction (AEG type I-III)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “Osteoporosis”]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “Chronic back pain”]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of lung cancer screening using low-dose computed tomography]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Target group-specific approach to insured persons during health check-ups]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a decision aid for aortic aneurysm interventions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Biomarker-based tests for deciding for or against adjuvant systemic chemotherapy in premenopausal women with primary breast cancer without lymph node involvement]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Biomarker-based tests for deciding for or against adjuvant systemic chemotherapy in primary breast cancer with involvement of 1-3 lymph nodes]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early detection of colorectal cancer in people with a family risk]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Rheumatoid Arthritis“]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Active knee motion devices in the treatment of anterior cruciate ligament ruptures – Update for Commission N16-01]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Screening for the early detection of familial hypercholesterolaemia in children and adolescents]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for colorectal cancer surgery – Update of Commission V22-02]
2024     Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for sickle cell disease and beta thalassaemia
2024     Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for sickle cell disease
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Opioid-sparing effects of IV acetaminophen for patients undergoing surgery
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aerosol therapy with inhalers during mechanical ventilation
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Intra-articular hyaluronic acid for osteoarthritis of the hip, shoulder, and ankle
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of antibiotic therapy for neisseria gonorrhoeae infection
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical and instrumental swallowing assessments for dysphagia
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketorolac for renal colic
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adults with substance use disorders
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adults with treatment-resistant depression or posttraumatic stress disorder: a 2023 update
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urethral discharge - diagnostic measures and pharmacological treatment]
2024     NIHR Health Technology Assessment programme Surgical versus non-surgical management of lateral compression type-1 pelvic fracture in adults 60 years and older: the L1FE RCT
2024     NIHR Health Technology Assessment programme Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT
2024     NIHR Health Technology Assessment programme Lower urinary tract symptoms in men: the TRIUMPH cluster RCT
2024     NIHR Health Technology Assessment programme A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)
2024     NIHR Health Technology Assessment programme Software with artificial intelligence-derived algorithms for analysing CT brain scans in people with a suspected acute stroke: a systematic review and cost-effectiveness analysis
2024     NIHR Health Services and Delivery Research programme Practices of falls risk assessment and prevention in acute hospital settings: a realist investigation
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early detection of vitamin B12 deficiency and other target diseases (homocystinuria, propionic acidaemia and methylmalonic acidaemia) in extended newborn screening (ENS)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Patisiran (hereditary transthyretin-mediated amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tebentafusp (uveal melanoma) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, other/unknown mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, RF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cannabidiol (tuberous sclerosis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cannabidiol (Dravet syndrome) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, gating mutation, heterozygous) – Benefit assessment according to §35a]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) – Addendum to Commission A23-88]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Addendum to Project A23-85]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vosoritide (achondroplasia, ≥ 2 years) – Addendum to Project A23-92]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Price and cost development of orphan drugs]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dalbavancin (acute bacterial skin and skin structure infections) – Addendum to Project A23-19]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirzepatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vosoritide (achondroplasia, ≥ 4 months) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix/estradiol/norethisterone acetate (endometriosis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cannabidiol (Lennox Gastaut syndrome) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary arterial pressure by means of implanted sensor for treatment optimization in heart failure stage NYHA III]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: a brief overview of indicators for care and service transitions of community-dwelling seniors with major neurocognitive disorder (MNCD) in Quebec]
2024     The Danish Health Technology Council (DHTC) [Assessment of non-surgical treatment of distal radius fractures in patients older than 65 years]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: an overview of emergency department visits and hospitalizations among young people aged 6 to 25 for mental health and psychosocial issues in 2022–2023, compared to the pre-pandemic (2016–2020) and pandemic periods (2020–2022) of COVID-19]
2024     NIHR Health Technology Assessment programme Effectiveness of septoplasty compared to medical management in adults with obstruction associated with a deviated nasal septum: the NAIROS RCT
2024     NIHR Health Technology Assessment programme Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: expressing wishes regarding goals of care and the decision about cardiopulmonary resuscitation]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: plasma sC5b-9 assay]
2024     NIHR Health Technology Assessment programme Use of selective gut decontamination in critically ill children: PICnIC a pilot RCT and mixed-methods study
2024     NIHR Health Services and Delivery Research programme The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding newborn screening for congenital adrenal hyperplasia to the Quebec newborn blood screening program]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: healthcare systems in the future: what priorities guide innovation?]
2024     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Implantable devices for left atrial appendage closure. Monitoring study]
2024     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Biodegradable stents for the treatment of benign esophageal strictures. Monitoring study]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: methodological report in support of the reflection guide supporting clinical and organizational practices in rehabilitation services for young people with adjustment problems aged 10 or older]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: type 2 diabetes screening and cardiovascular risk assessment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: dosing of a new generation anti-seizure panel by LC-MS/MS]
2024     Basque Office for Health Technology Assessment (OSTEBA) [Use of self-sampling for the detection of human papillomavirus in cervical cancer screening]
2024     Basque Office for Health Technology Assessment (OSTEBA) [Exoskeletons for the functional recovery of walking ability in patients with central nervous system disorders such as multiple sclerosis, stroke, and traumatic spinal injury]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Calcitonin gene-related peptide antagonists for the prevention of migraine - summary of the BAG /RACS HTA report 2023]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Biomarkers in Parkinson's Disease]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Role of public contributions to the development of health innovations and its integration in value assessment and pricing/reimbursement decisions
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Liposuction for the removal of subcutaneous (large) lipomas]
2024     Scottish Health Technologies Group (SHTG) Green theatres
2024     Agency for Care Effectiveness (ACE) Cochlear implants for children with single-sided deafness
2024     Agency for Care Effectiveness (ACE) Wingspan stent system for intracranial atherosclerotic stenosis
2024     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma